GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Sartorius Stedim Biotech SA (WBO:DIM) » Definitions » Debt-to-Asset

Sartorius Stedim Biotech (WBO:DIM) Debt-to-Asset : 0.35 (As of Sep. 2024)


View and export this data going back to 2020. Start your Free Trial

What is Sartorius Stedim Biotech Debt-to-Asset?

Sartorius Stedim Biotech's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2024 was €32 Mil. Sartorius Stedim Biotech's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2024 was €2,800 Mil. Sartorius Stedim Biotech's Long-Term Debt & Capital Lease ObligationTotal Assets for the quarter that ended in Sep. 2024 was €7,998 Mil. Sartorius Stedim Biotech's debt to asset for the quarter that ended in Sep. 2024 was 0.35.


Sartorius Stedim Biotech Debt-to-Asset Historical Data

The historical data trend for Sartorius Stedim Biotech's Debt-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sartorius Stedim Biotech Debt-to-Asset Chart

Sartorius Stedim Biotech Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Debt-to-Asset
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.08 0.21 0.16 0.22 0.48

Sartorius Stedim Biotech Quarterly Data
Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Jun24 Sep24
Debt-to-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.26 0.48 0.48 0.36 0.35

Competitive Comparison of Sartorius Stedim Biotech's Debt-to-Asset

For the Medical Instruments & Supplies subindustry, Sartorius Stedim Biotech's Debt-to-Asset, along with its competitors' market caps and Debt-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Sartorius Stedim Biotech's Debt-to-Asset Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Sartorius Stedim Biotech's Debt-to-Asset distribution charts can be found below:

* The bar in red indicates where Sartorius Stedim Biotech's Debt-to-Asset falls into.



Sartorius Stedim Biotech Debt-to-Asset Calculation

Debt to Asset measures the financial leverage a company has.

Sartorius Stedim Biotech's Debt-to-Asset for the fiscal year that ended in Dec. 2023 is calculated as

Sartorius Stedim Biotech's Debt-to-Asset for the quarter that ended in Sep. 2024 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Sartorius Stedim Biotech  (WBO:DIM) Debt-to-Asset Explanation

In the calculation of Debt-to-Asset, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Assets.


Sartorius Stedim Biotech Debt-to-Asset Related Terms

Thank you for viewing the detailed overview of Sartorius Stedim Biotech's Debt-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


Sartorius Stedim Biotech Business Description

Address
Otto-Brenner-Strasse 20, Goettingen, DEU, 37079
Sartorius Stedim Biotech, or SSB, is a leading provider of bioprocessing solutions. Its sells equipment and consumables for fermentation, filtration, fluid management, purification, and cell culture media for manufacturing biologic drugs, and has a focus on single-use technology, or SUT. It is a subsidiary of Sartorius AG, which has a 74% ownership and 85% voting control. The business is geographically diverse.

Sartorius Stedim Biotech Headlines